

Elizabeth Harford-Wright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11987371/publications.pdf>

Version: 2024-02-01

15
papers

332
citations

932766

10
h-index

996533

15
g-index

16
all docs

16
docs citations

16
times ranked

563
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological targeting of apelin impairs glioblastoma growth. <i>Brain</i> , 2017, 140, 2939-2954.	3.7	70
2	Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. <i>Neuroscience Letters</i> , 2010, 481, 26-29.	1.0	42
3	Differential Effects of 670 and 830 nm Red near Infrared Irradiation Therapy: A Comparative Study of Optic Nerve Injury, Retinal Degeneration, Traumatic Brain and Spinal Cord Injury. <i>PLoS ONE</i> , 2014, 9, e104565.	1.1	39
4	Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis. <i>EMBO Journal</i> , 2020, 39, e102030.	3.5	33
5	Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 1-12.	1.7	26
6	Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors. <i>PLoS ONE</i> , 2014, 9, e97002.	1.1	21
7	Î²-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability. <i>Oncotarget</i> , 2016, 7, 66865-66879.	0.8	20
8	Desert Hedgehog/Patch2 Axis Contributes to Vascular Permeability and Angiogenesis in Glioblastoma. <i>Frontiers in Pharmacology</i> , 2015, 6, 281.	1.6	15
9	NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 344-354.	0.7	14
10	Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. <i>Cancer Cell International</i> , 2013, 13, 5.	1.8	13
11	Apelin, the Devil Inside Brain Tumors. <i>Journal of Experimental Neuroscience</i> , 2018, 12, 117906951875968.	2.3	9
12	Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface. <i>Recent Patents on CNS Drug Discovery</i> , 2011, 6, 31-40.	0.9	8
13	Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. <i>Journal of Neuroimmunology</i> , 2012, 250, 59-65.	1.1	8
14	The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours. <i>Recent Patents on CNS Drug Discovery</i> , 2013, 8, 13-23.	0.9	7
15	Neutralizing gp130 interferes with endothelial-mediated effects on glioblastoma stem-like cells. <i>Cell Death and Differentiation</i> , 2017, 24, 384-384.	5.0	5